Method to Promote Wound Healing
Wound healing is impaired in irradiated animals. Substance P and its active analogs promote wound healing in irradiated animals. Substance P and its analogs can be used to treat animals irradiated by a nuclear weapon, a nuclear accident, or a therapeutic regimen, for example. Wounds which are susceptible to such treatment include surgical wounds, weapons wounds, disease-caused wounds, bed sores, diabetic ulcers, etc.
1 . A method of stimulating wound healing in a radiation-exposed mammal, comprising:
administering an effective amount of Substance P or an analog thereof to a mammal that has been exposed to radiation and that has a wound, wherein said analog is selected from the group consisting of [Met-OH 11 ]-substance P, [Met-OMe 11 ]-substance P, [Nle 11 ]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr 8 ]-substance P, [p-Cl-Phe 7,8 ]-substance P, [Sar 9 ,Met (O 2 ) 11 ]-substance P, and analogs having the amino acid backbone RPKPQQFFGLM-NH 2 , whereby healing of the wound is stimulated.
2 . The method of claim 1 wherein Substance P is administered.
3 . The method of claim 1 wherein [Met-OH 11 ]-Substance P is administered.
4 . The method of claim 1 wherein [Met-OMe 11 ]-Substance P is administered.
5 . The method of claim 1 wherein [Nle 11 ]-Substance P is administered.
6 . The method of claim 1 wherein [Pro 9 ]-Substance P is administered.
7 . The method of claim 1 wherein [Sar 9 ]-Substance P is administered.
8 . The method of claim 1 wherein [Tyr 8 ]-Substance P is administered.
9 . The method of claim 1 wherein [p-Cl-Phe 7,8 ]-Substance P is administered.
10 . The method of claim 1 wherein [Sar 9 ,Met (O 2 ) 11 ]-Substance P is administered.
11 . The method of claim 1 wherein the step of administering is performed by injection into a muscle.
12 . The method of claim 1 wherein the step of administering is performed by topical administration.
13 . The method of claim 1 wherein the step of administering is performed by intravenous-administration.
14 . The method of claim 1 wherein the step of administering is performed by administration of an aerosol to the nose.
15 . The method of claim 1 wherein the step of administering is performed by administration of an aerosol to the lungs.
16 . The method of claim 1 wherein the mammal is a human.
17 . The method of claim 1 wherein the mammal is a rodent.
18 . The method of claim 1 wherein the mammal is a bovid.
19 . The method of claim 1 wherein the mammal is a dog.
20 . The method of claim 1 wherein the mammal is a cat.
21 . The method of claim 1 wherein the mammal was exposed to fall-out from a nuclear explosion.
22 . The method of claim 1 wherein the mammal was exposed to therapeutic radiation.
23 . The method of claim 1 wherein the wound is a surgical wound.
24 . The method of claim 1 wherein the wound is a pressure wound.
25 . The method of claim 1 wherein the mammal was exposed to ionizing radiation.
26 . The method of claim 1 wherein the mammal was exposed to gamma radiation.
27 . The method of claim 1 wherein the mammal was occupationally exposed to radiation.
28 . The method of claim 1 wherein the wound is cutaneous.
29 . The method of claim 1 wherein the wound is muscular.
30 . The method of claim 1 wherein the wound is an osseus lesion.
31 . The method of claim 1 wherein the wound is a gastrointestinal anastamosis.
32 . The method of claim 1 wherein the wound is a burn wound.
33 . The method of claim 1 wherein the wound is a decubitus ulcer.